



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

Virginia Medicaid
Drug Utilization Review (DUR) Board
Quarterly Meeting
2pm
Thursday, March 15, 2012
DMAS Board Room 13th Floor

Draft Agenda

1. Call to Order and Introductions – Randy Ferrance, MD, Chair
2. Minutes
 - a. Approval of Minutes from the November 17, 2011 meeting
3. New Drugs
 - a. Jakafi (ruxolitinib)
 - b. Eylea (aflibercept)
 - c. Ferriprox (deferiprone)
 - d. Onfi (Clobazam)
 - e. Asclrea (polidocanol)
 - f. Promacta (eltrombopag)
 - g. Edarbyclor (azilsartan medoxomil and chlorthalidone)
 - h. Kalydeco (ivacaftor)
4. Old Business:
 - a. Celexa and abnormal heart rhythms FDA warning
 - b. Firazyr
 - c. Lazanda
 - d. Xalkori
 - e. Zelboraf
5. Reports:
 - a. ProDUR
 - b. RetroDUR



A xerox Company



COMMONWEALTH of VIRGINIA

Department of Medical Assistance Services

DRUG UTILIZATION REVIEW PROGRAM

- c. Ad hocs
- d. Utilization Analysis Reports based on Claims

- 6. Future Topics
- 7. Other Business
- 8. Adjournment



A **xerox**  Company